Product Name :
LQZ-7I
Description:
LQZ-7I is a malarial protease PfSUB1 inhibitor. LQZ-7I showed significantly improved activity and is the focus of this work. LQZ-7 when given orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors. The data obtained utilizing LQZ-7I in both in vitro and in vivo studies highlights its potential as a lead for further development, which may yield a potential cancer therapeutic by targeting the survivin protein directly.
CAS:
195822-23-2
Molecular Weight:
348.35
Formula:
C20H14F2N4
Chemical Name:
2,3-Quinoxalinediamine, N,N’-bis(4-fluorophenyl)-
Smiles :
FC1C=CC(=CC=1)NC1=NC2=CC=CC=C2N=C1NC1C=CC(F)=CC=1
InChiKey:
DKPCKOKYSVPFEB-UHFFFAOYSA-N
InChi :
InChI=1S/C20H14F2N4/c21-13-5-9-15(10-6-13)23-19-20(24-16-11-7-14(22)8-12-16)26-18-4-2-1-3-17(18)25-19/h1-12H,(H,23,25)(H,24,26)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
LQZ-7I is a malarial protease PfSUB1 inhibitor. LQZ-7I showed significantly improved activity and is the focus of this work. LQZ-7 when given orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors. The data obtained utilizing LQZ-7I in both in vitro and in vivo studies highlights its potential as a lead for further development, which may yield a potential cancer therapeutic by targeting the survivin protein directly.{{L-Carnosine} MedChemExpress|{L-Carnosine} Metabolic Enzyme/Protease|{L-Carnosine} Protocol|{L-Carnosine} Description|{L-Carnosine} supplier|{L-Carnosine} Epigenetics} |Product information|CAS Number: 195822-23-2|Molecular Weight: 348.{{BAI1} web|{BAI1} Modulator|{BAI1} NF-κB|{BAI1} Technical Information|{BAI1} Purity|{BAI1} supplier} 35|Formula: C20H14F2N4|Synonym:|LQZ7I|LQZ-7I|LQZ 7I|Chemical Name: 2,3-Quinoxalinediamine, N,N’-bis(4-fluorophenyl)-|Smiles: FC1C=CC(=CC=1)NC1=NC2=CC=CC=C2N=C1NC1C=CC(F)=CC=1|InChiKey: DKPCKOKYSVPFEB-UHFFFAOYSA-N|InChi: InChI=1S/C20H14F2N4/c21-13-5-9-15(10-6-13)23-19-20(24-16-11-7-14(22)8-12-16)26-18-4-2-1-3-17(18)25-19/h1-12H,(H,23,25)(H,24,26)|Technical Data|Appearance: Solid Power.PMID:25023702 |Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|How to use|In Vitro:|LQZ-7I has improved cytotoxicity with IC50s of 3.1 µM against C4-2 cells and 4.8 µM against PC-3 cells compared with the parent compound LQZ-7. LQZ-7I (10 µM; 0-6 hours) treatment reduces the expression of survivin. However, LQZ-7I does not reduce the expression of XIAP, CIAP1, and CIAP2. LQZ-7I may be selective to its intended target survivin.|In Vivo:|LQZ-7I (100 mg/kg; oral gavage every other day for a total of ten treatments) significantly suppresses tumor growth without any notable adverse effect on the mice.|References:|Peery, Robert; Kyei-Baffour, Kwaku; Dong, Zizheng; Liu, Jianguo; de Andrade Horn, Pedro; Dai, Mingji; Liu, Jing-Yuan; Zhang, Jian-Ting Synthesis and Identification of a Novel Lead Targeting Survivin Dimerization for Proteasome-Dependent Degradation, Journal of Medicinal Chemistry (2020), Ahead of Print.Products are for research use only. Not for human use.|